Related Experiment Video
Updated: Aug 5, 2026

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Chemotherapy plus Erlotinib versus Chemotherapy Alone for Treating Advanced Non-Small Cell Lung Cancer: A
1Department of Pulmonary, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai, China.
Combining chemotherapy with erlotinib improves progression-free survival (PFS) in advanced non-small cell lung cancer (NSCLC), particularly for never-smokers and those with EGFR mutations. Intercalated administration shows promising efficacy.
Area of Science:
- Oncology
- Pharmacology
- Clinical Trials
Background:
- Chemotherapy combined with erlotinib for advanced non-small cell lung cancer (NSCLC) efficacy is debated.
- This meta-analysis evaluates evidence comparing combination therapy to chemotherapy alone.
Purpose of the Study:
- To compare the efficacy and safety of chemotherapy plus erlotinib versus chemotherapy alone in advanced NSCLC.
- To identify patient subgroups benefiting most from combination therapy.
Main Methods:
- Systematic literature search of EMBASE, PubMed, and Cochrane Central Register.
- Inclusion of nine randomized controlled trials (RCTs) involving 3599 patients.
- Meta-analysis of progression-free survival (PFS) and overall survival (OS) data.
Main Results:
- Chemotherapy plus erlotinib significantly improved PFS (HR=0.76) versus chemotherapy alone, but not OS (HR=0.94).
- Intercalated erlotinib plus chemotherapy improved both PFS (HR=0.67) and OS (HR=0.82).
- Significant PFS benefit observed in never-smokers and EGFR-mutated NSCLC patients.
Conclusions:
- Combination of chemotherapy and erlotinib is a viable treatment for advanced NSCLC.
- This combination is particularly effective for never-smokers and EGFR mutation-positive NSCLC.
- Intercalated administration represents an effective strategy for combining these treatments.
More Related Videos
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
Related Concept Videos
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...